Neurogene (NASDAQ:NGNE) Price Target Raised to $72.00 at Robert W. Baird

Neurogene (NASDAQ:NGNE) had its price target hoisted by Robert W. Baird from $54.00 to $72.00 in a research report report published on Tuesday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Separately, HC Wainwright decreased their target price on Neurogene from $51.00 to $49.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $63.33.

Neurogene Trading Down 12.0 %

Shares of NGNE opened at $34.52 on Tuesday. Neurogene has a 52-week low of $12.49 and a 52-week high of $74.49. The company has a 50-day simple moving average of $47.11 and a 200-day simple moving average of $40.11.

Institutional Trading of Neurogene

Institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC lifted its holdings in Neurogene by 319.4% in the 3rd quarter. Barclays PLC now owns 14,859 shares of the company’s stock valued at $623,000 after purchasing an additional 11,316 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Neurogene in the third quarter valued at approximately $324,000. Wellington Management Group LLP purchased a new position in shares of Neurogene during the third quarter valued at approximately $767,000. State Street Corp lifted its stake in shares of Neurogene by 17.5% during the third quarter. State Street Corp now owns 246,540 shares of the company’s stock valued at $10,345,000 after buying an additional 36,687 shares during the period. Finally, RTW Investments LP boosted its position in Neurogene by 6.0% during the third quarter. RTW Investments LP now owns 1,135,256 shares of the company’s stock worth $47,635,000 after acquiring an additional 64,691 shares during the last quarter. 52.37% of the stock is currently owned by hedge funds and other institutional investors.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.